| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.61B | 11.76B | 11.01B | 10.94B | 10.93B | 9.56B |
| Gross Profit | 8.44B | 6.83B | 7.92B | 7.68B | 7.82B | 6.91B |
| EBITDA | 6.13B | 5.21B | 7.20B | 7.08B | 7.26B | 6.40B |
| Net Income | 1.42B | 1.61B | 2.81B | 2.72B | 2.59B | -1.54B |
Balance Sheet | ||||||
| Total Assets | 234.73B | 234.97B | 231.45B | 226.54B | 238.03B | 224.75B |
| Cash, Cash Equivalents and Short-Term Investments | 7.48B | 10.82B | 6.34B | 5.79B | 9.14B | 6.79B |
| Total Debt | 49.56B | 58.06B | 50.97B | 46.25B | 46.22B | 39.10B |
| Total Liabilities | 80.75B | 82.28B | 76.54B | 71.33B | 73.54B | 65.41B |
| Stockholders Equity | 97.65B | 95.78B | 94.36B | 92.82B | 95.84B | 92.11B |
Cash Flow | ||||||
| Free Cash Flow | 1.74B | 5.04B | 3.91B | 378.00M | -1.14B | -546.00M |
| Operating Cash Flow | 3.69B | 5.21B | 4.02B | 3.10B | 1.74B | 2.58B |
| Investing Cash Flow | -3.13B | -3.07B | -2.85B | -3.20B | -1.44B | -2.21B |
| Financing Cash Flow | -455.00M | 2.38B | -566.00M | -4.25B | 1.82B | 2.06B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$21.17B | 14.89 | 1.48% | 5.62% | -9.78% | -29.50% | |
70 Outperform | HK$143.40B | 23.78 | 1.89% | 6.20% | -19.91% | -6.92% | |
65 Neutral | $2.17B | 12.19 | 3.79% | 4.94% | 3.15% | 1.96% | |
53 Neutral | HK$11.16B | -6.18 | -3.35% | 5.93% | 1.37% | -157.43% | |
49 Neutral | HK$2.05B | -3.97 | -1.67% | ― | -21.25% | 24.06% | |
44 Neutral | HK$18.93B | -1.16 | -9.54% | ― | -40.92% | -42.67% |
Hang Lung Group has announced the planned retirement of Mr. Weber W.P. Lo, its Chief Executive Officer and Executive Director, effective on or before August 31, 2026. The Boards have begun a thorough search for a successor to ensure a seamless leadership transition, acknowledging Mr. Lo’s significant contributions to the organization. This leadership change reflects the company’s focus on continuity and future growth, with implications for its operational strategy and long-term governance structure.
The most recent analyst rating on (HK:0010) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Hang Lung Group stock, see the HK:0010 Stock Forecast page.